arsenic trioxide + ascorbic acid + bortezomib + dexamethasone

This is a four-drug combination regimen consisting of arsenic trioxide, ascorbic acid (vitamin C), bortezomib, and dexamethasone. Each component has a distinct mechanism of action: - Arsenic trioxide induces apoptosis and promotes differentiation in malignant cells, particularly in acute promyelocytic leukemia. - Ascorbic acid acts as an antioxidant and may enhance the cytotoxic effects of certain chemotherapeutics. - Bortezomib is a proteasome inhibitor that disrupts protein degradation pathways, leading to apoptosis in cancer cells. - Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties; it also induces apoptosis in certain hematologic malignancies. This specific four-drug combination does not have an established brand name or widespread clinical use under this exact formulation. It may be considered for investigational or off-label use in hematologic malignancies such as multiple myeloma or other cancers where synergistic effects are hypothesized based on the mechanisms of each agent. However, most published regimens for multiple myeloma involve combinations like lenalidomide-bortezomib-dexamethasone rather than including arsenic trioxide and ascorbic acid[1][2][3][4][5].